Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Turn Therapeutics Inc.NASDAQ: TTRX
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow of -$12.23K in Q1 FY2026
Q1 FY2026 investing cash flow was -$12.23K. Trailing-twelve-month investing cash flow was -$165.21K.
Context
- Investing cash flow grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly investing cash flow holds near -$12.23K or moves back toward the trailing-twelve-month quarterly average of -$41.3K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (152.99K) USD
- Year-over-year change
- -53.8%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (152.99K) | -53.8% |
| FY2024 | 2024-12-31 | (99.48K) | -124.5% |
| FY2023 | 2023-12-31 | (44.31K) | — |
Investing Cash Flow vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 investing cash flow of $165.21K is the 6th largest of the 9 companies compared; the peer median is $4.5K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $99.49M | +687.2% | — | — | |
| LTM Mar 2026 | $70.09M | +48437.2% | — | 56.6% | |
| LTM Mar 2026 | $55.01M | -5.3% | — | 365.8% | |
| LTM Apr 2026 | $1.47M | -83.0% | — | — | |
| LTM Mar 2026 | $233.16K | — | +232.7% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $165.21K | — | — | — |
| LTM Mar 2026 | $9K | +325.0% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $0 | -100.0% | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding TTRX) | $4.5K | +159.8% | +232.7% | 56.6% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 640.26K | 352.83K | 419.25K |
| Change in Working Capital | 229.74K | (1.86K) | 2.37M |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 2.26M |
| Other Working Capital | 229.74K | (1.86K) | 105.03K |
| Other Non-Cash Items | 662 | 8.65K | (2.21M) |
| Operating Cash Flow | (1.38M) | (1.36M) | (2.56M) |
| Capital Expenditures | (44.31K) | (99.48K) | (152.99K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (152.99K) |
| Investing Cash Flow | (44.31K) | (99.48K) | (152.99K) |
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued | 500K | 1.15M | 6.92M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 500K | 1.15M | 6.92M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (921.99K) | (308.4K) | 4.2M |
| Free Cash Flow | (1.42M) | (1.46M) | (2.72M) |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.